Literature DB >> 12122103

Herpes simplex viruses: is a vaccine tenable?

Richard J Whitley1, Bernard Roizman.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12122103      PMCID： PMC151069          DOI： 10.1172/JCI16126

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  46 in total

Review 1.  Genetically engineered HSV in the treatment of glioma: a review.

Authors:  J M Markert; G Y Gillespie; R R Weichselbaum; B Roizman; R J Whitley
Journal:  Rev Med Virol       Date:  2000 Jan-Feb       Impact factor: 6.989

2.  Vaccination for recurrent herpes simplex infection; initiation of a new disease site following the use of unmodified material containing the live virus.

Authors:  M P LAZAR
Journal:  AMA Arch Derm       Date:  1956-01

Review 3.  [Herpes simplex virus, type II: microbiology and clinical experiences with attenuated vaccine].

Authors:  T Nasemann; G Schaeg
Journal:  Hautarzt       Date:  1973-04       Impact factor: 0.751

4.  [Therapy of recurrent Herpes simplex].

Authors:  J Söltz-Szöts
Journal:  Z Haut Geschlechtskr       Date:  1971-04-15

5.  Efficacy of a nucleic acid free herpetic subunit vaccine.

Authors:  R Cappel; F de Cuyper; F Rickaert
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions.

Authors:  E S Mocarski; L E Post; B Roizman
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

7.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Authors:  R Rampling; G Cruickshank; V Papanastassiou; J Nicoll; D Hadley; D Brennan; R Petty; A MacLean; J Harland; E McKie; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

8.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

9.  The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.

Authors:  S-M Chung; S J Advani; J D Bradley; Y Kataoka; K Vashistha; S Y Yan; J M Markert; G Y Gillespie; R J Whitley; B Roizman; R R Weichselbaum
Journal:  Gene Ther       Date:  2002-01       Impact factor: 5.250

10.  Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

Authors:  E N Kitces; P S Morahan; J G Tew; B K Murray
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441
View more
  17 in total

1.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

Review 2.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

3.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Michael G Edwards; Ryan Heiser; Joanne E Streib; Brittany Richers; Clifton F Hall; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

4.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

5.  Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.

Authors:  Brendon M Stiles; Prasad S Adusumilli; Stephen F Stanziale; David P Eisenberg; Amit Bhargava; Teresa H Kim; Mei-Ki Chan; Rumana Huq; Mithat Gonen; Yuman Fong
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

Review 6.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

7.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells.

Authors:  Ronen Borenstein; Oded Singer; Adi Moseri; Niza Frenkel
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  A lipid-peptide microbicide inactivates herpes simplex virus.

Authors:  Charles E Isaacs; Jun Hua Jia; Weimin Xu
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo.

Authors:  Luka Cicin-Sain; Wolfram Brune; Ivan Bubic; Stipan Jonjic; Ulrich H Koszinowski
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.